title: Future considerations for dendritic cell immunotherapy against chronic viral infections.
abstract: Dendritic cells (DCs) are multifunctional cells that are pivotal in immune defense. As such they have been explored as vaccine carriers, largely in cancer immunotherapy and against some infectious diseases including HIV and viral hepatitis. However, while the use of DCs as vaccine carrier has shown some promise in cancer immunotherapy, this approach is laborious and is subject to strict quality control, which makes it expensive. Furthermore, in some individuals chronically infected with HIV, HCV and/or HBV the numbers of circulating DCs are reduced and/or their functions impaired. In vivo expansion and mobilization of DCs with Flt3L in combination with antigen and/or adjuvant targeting to critical DC receptors may be a more effective approach to control viral replication in chronically infected HIV, HBV and/or HCV patients than current DC immunotherapy approaches.
authors.affiliation: VIDO-Intervac, University of Saskatchewan, 120 Veterinary Road, Saskatoon, SK, S7N 5E3, Canada.
authors.forename: Ethel
authors.initials: E
authors.lastname: Atanley
authors.forename: Sylvia
authors.initials: S
authors.lastname: van Drunen Littel-van den Hurk
mesh_terms: D000818:Animals; D002908:Chronic Disease; D003713:Dendritic Cells / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D019694:Hepatitis B, Chronic / Q000276:immunology / Q000628:therapy*; D019698:Hepatitis C, Chronic / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*
keywords: Flt3L; HBV immunotherapy; HCV; HIV; dendritic cells; endocytic receptors